Gilead Sciences, Inc. $GILD Shares Sold by Patton Albertson Miller Group LLC

Patton Albertson Miller Group LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 55.2% during the fourth quarter, HoldingsChannel reports. The firm owned 3,344 shares of the biopharmaceutical company’s stock after selling 4,116 shares during the quarter. Patton Albertson Miller Group LLC’s holdings in Gilead Sciences were worth $410,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GILD. Massachusetts Financial Services Co. MA lifted its position in shares of Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Gilead Sciences by 154.3% during the third quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after purchasing an additional 1,874,508 shares in the last quarter. Invesco Ltd. lifted its position in shares of Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares in the last quarter. Finally, Danske Bank A S acquired a new position in shares of Gilead Sciences during the third quarter worth $133,049,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q1 results beat estimates — Gilead reported $2.03 EPS vs. a $1.89 consensus and revenue of $6.96B vs. ~$6.91B, showing underlying quarter strength. Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 sales forecast, indicating revenue strength despite other headwinds. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
• Neutral Sentiment: Full‑year revenue guidance was issued at roughly $30.0–30.4B, near analyst consensus — so sales expectations are roughly intact even as profit guidance shifted. Gilead Press Release / Slide Deck
• Neutral Sentiment: Shareholders approved the board and executive pay plans at the 2026 meeting — governance items cleared without disruption. Gilead Shareholders Back Board, Pay Plans at 2026 Meeting
• Negative Sentiment: Company withdrew prior profit guidance and now expects an adjusted FY2026 loss of $1.05 to $0.65 per share (versus prior ~$8.45–8.85 outlook and analyst expectations near $8.65), a dramatic revision that hits valuation and investor confidence. Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
• Negative Sentiment: Management attributes the profit swing to acquisition‑related charges and financing costs tied to recent deals — these one‑time and financing items meaningfully depress reported earnings for the year. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Barclays started coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price on the stock. Morgan Stanley upped their price target on shares of Gilead Sciences from $171.00 to $175.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Scotiabank upped their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 11th. Finally, UBS Group upped their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a report on Monday, January 26th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $157.35.

Gilead Sciences Trading Down 1.6%

GILD opened at $134.06 on Friday. The stock has a market capitalization of $166.40 billion, a PE ratio of 19.80, a P/E/G ratio of 1.80 and a beta of 0.31. Gilead Sciences, Inc. has a 12-month low of $95.29 and a 12-month high of $157.29. The firm’s fifty day moving average price is $139.59 and its 200 day moving average price is $132.87. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is 48.45%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the chief financial officer directly owned 176,191 shares of the company’s stock, valued at approximately $24,835,883.36. This represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the sale, the chief executive officer directly owned 632,567 shares in the company, valued at $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 63,000 shares of company stock valued at $9,238,250. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.